The Incretin System and Cardiovascular Risk: Effects of Incretin-Targeted Therapies

Current Cardiovascular Risk Reports

Volumn 5, Issue 1, 2011, Pages 62-69

  Mundil, Dhanwantee ^a,b,c   Noyan Ashraf, M Hossein ^a,b,c   Husain, Mansoor ^a,b,c,d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e NONE   (Canada)

Author keywords

Cardiovascular disease; Diabetes mellitus; Dipeptidyl peptidase 4 inhibitor; GLP 1 receptor agonist; Glucagon like peptide 1; Incretins

Indexed keywords

CORTICOSTEROID; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; INCRETIN; INSULIN; INSULIN GLARGINE; LIPID; LIRAGLUTIDE; METFORMIN; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ADRENERGIC SYSTEM; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS GRAFT; DRUG WITHDRAWAL; GENE DELETION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; VASODILATATION; WEIGHT REDUCTION;

EID: 84872082661     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-010-0141-5     Document Type: Review

References (53)

1. The World Health Report 2004. World Health Organization. Available at http://www. who. int/whr/2004/en/report04_en. pdf. Accessed October 2010.
2. Mensah GA, Mokdad AH, Ford ES, et al.: State of disparities in cardiovascular health in the United States. Circulation 2005, 111: 1233-1241.
3. Lilly LS: Pathophysiology of heart disease. In Pathophysiology of Heart Disease; A collaborative project of medical students and faculty. Edited by Lippincott, Williams & Wilkins; 2006: Chapter 1.
4. Uwaifo GI and Ratner RE: Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. Am J Cardiol 2007, 99: 51B-67B.
5. Drucker DJ, Sherman SI, Gorelick FS et al.: Incretin-based therapies for the treatment of Type 2 diabetes. Diabetes Care 2010, 33: 428-433.
6. •• Ban K, Noyan-Ashraf MH, Hoefer J, et al,: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117: 2340-2350. This is the first study to show expression of the GLP-1R on cardiomyocytes, endothelial cells, and vascular smooth muscle cells. This study also suggested that the metabolite GLP-1(9-36) has effects independent of the known GLP-1R on vasodilation and cardioprotection from I/R injury.
7. Barragan JM, Rodriguez RE, Blazquez E: Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol Endocrinol Metab 1994, 266: E459-466.
8. Barragan JM, Rodriguez RE, Eng J, Blazquez E: Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept 1996, 67: 63-68.
9. Barragan JM, Eng J, Rodriguez R, Blazquez E: Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol Endocrinol Metab 1999, 277: E784-791.
10. Yamamoto H, Lee CE, Marcus JN, et al.: Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002, 110: 43-52.
11. Yu M, Moreno C, Hoagland KM, et al.: Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003, 21: 1125-1135.
12. • Hirata K, Kume S, Araki SI, et al.: Exendin-4 has antihypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 2009, 380: 44-49. This study shows that salt-sensitive hypertension in diabetic mice can be attenuated by exendin-4, acting directly on GLP-1R in the kidney and by regulating salt handling.
13. • Laugero KD, Stonehouse AH, Guss S, et al.: Exenatide improves hypertension in a rat model of the metabolic syndrome. Metab Syndr Relat Disord 2009, 7: 327-333. This study demonstrates that continuous exenatide treatment can reverse hypertension in a rat model of metabolic syndrome, independent of changes in body weight.
14. Gill A, Hoogwerf BJ, Burger J, et al.: Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 2010, 9: 1-7.
15. Okerson T, Yan P, Stonehouse A, Brodows R: Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 2010, 23: 334-9.
16. • Apovian CM, Bergental RM, Cuddihy RM, et al.: Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 2010, 123: 468. e9-468. e17. The only placebo-controlled study comparing effect of lifestyle modification with and without exenatide treatment on blood pressure and body weight. Exenatide plus lifestyle modification significantly reduced SBP, DBP, and body weight compared to lifestyle modification alone in obese diabetic patients.
17. Zinman B, Gerich G, Buse JB, et al. The LEAD-4 Study Investigators: Efficacy and safety of the human glugacon-like peptide -1 analog liraglutide in combination with metformin thialidinedione in patients with type2 diabetes (LEAD-4 Met + TZD). Diabetes Care 2009, 32: 1224-1230.
18. Russell-Jones D, Vaag A, Schmitz O, et al. on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met + SU Study Group: Liraglutide versus insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia 2009, 52: 2046-2055.
19. Buse JB, Sesti G, Schmidt WE, et al. For Liraglutide Effect and Action in Diabetes 5 (LEAD-6) Study Group: Switching to once-daily Liraglutide from twice daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010, 33: 1300-1303.
20. • Bergenstal RM, Wysham C, MacConell L, et al. for the DURATION-2 Study Group: Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010, 376: 431-39. This is one of few clinical studies comparing effect of the GLP-1R agonist exenatide versus the DPP-4 inhibitor sitagliptin on blood pressure as a secondary endpoint. Exenatide reduced SBP more than sitagliptin, with no change in DBP.
21. Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al.: Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009, 11: 611-22.
22. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008, 146: 243-249.
23. Brown SB, Libonati JR, Selak MA, et al.: Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart. Cardiovasc Drug Ther 2010, 24: 197-205.
24. •• Sauve M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010, 59: 1063-1073. This study demonstrates that either pre-treatment with the DPP-4 inhibitor, sitagliptin, or genetic deletion of DPP-4 can significantly improve survival from chronic left anterior descending artery ligation-induced MI and improve recovery of left ventricular developed pressure after I/R injury.
25. Bose AK, Mocanu MM, Carr RD, et al.: Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54: 146-151.
26. Nikolaidis LA, Doverspike A, Hentosz T, et al.: Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 2005, 312: 303-308.
27. Kavianipour M, Ehlers MR, Malmberg K, et al.: Glucagon-like peptide (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 2003, 24: 569-578.
28. Timmers L, Henriques JP, de Kleijn DP, et al.: Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. Journal of the American College of Cardiology 2009, 53: 501-510.
29. Kristensen J, Mortensen U, Schmidt M, et al. Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovascular Disorders 2009, 9: 31.
30. •• Noyan-Ashraf MH, Momen MA, Ban K, et al.: GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58: 975-983. This study shows that pre-treatment with the GLP-1R agonist liraglutide reduced infarct size and upregulated the expression and or activation of pro-survival cardioprotective genes in a mouse model of myocardial infarction.
31. Nikolaidis LA, Mankad S, Sokos GG, et al.: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109: 962-965.
32. Sokos GG, Bolukoglu H, German J, et al.: Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007, 100: 824-829.
33. Halbirk M, Nørrelund H, Møller N, et al:. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 2010, 298: H1096-102.
34. Golpon HA, Puechner A, Welte T, et al.: Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001, 102: 81-86.
35. Nystrom T, Gonon AT, Sjoholm A, et al.: Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005, 125: 173-177.
36. Green BD, Hand KV, Dougan JE, et al.: GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving K(ATP) and cAMP. Arch Biochem Biophys 2008, 478: 136-142.
37. Liraglutide effect and actions in diabetes: Evaluation of cardiovascular outcome results-a long term evaluation (LEADER). Available at htttp://www. clinicaltrials. gov/ct2/show/NCT01179048. Accessed October 2010.
38. Williams-Herman D, Engel SS, Round E, et al.: Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10, 246 patients with type 2 diabetes. BMC Endocrine Disorders 2010, 10: 1-21.
39. Bethel MA, Green J, Califf RM, et al.: Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (abstract). Diabetologia 2009, 52(suppl): S480.
40. Frederich R, Alexander JH, Fiedorek FT, et al.: A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010, 122: 16-27.
41. Does saxagliptin reduce the risk of cardiovascular events when used alone or added to other diabetes medications (SAVOR-TIMI 53). Available at http://www. clinicaltrial. gov/ct2/show/NCT01107886. Accessed October 2010.
42. Moretto TJ, Milton DR, Ridge TD, MacConell et al.: Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic dug-naïve patients with type 2 diabetes: a randomized double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics 2008, 30: 1448-1460.
43. Klonoff DC, Buse JB, Nielsen LL, et al.: Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr med res Op. 2008, 24: 275-286.
44. Schwartz EA, Koska J, Mullin MP et al.: Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 2010, 212: 217-222.
45. Varanasi A Chaudhuri A, Dhindsa S, et al.: Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure CRP and triglyceride concentrations. Endocr Pract 2010, 14: 1-20.
46. • Gardiner SM, March JE, Kemp PA et al.: Autonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats. Br J Pharmacol 2008, 154: 60-71. This study demonstrates the involvement of beta-adrenergic receptors in the vasodilator and cardiovascular actions of exendin-4, but also an autonomic nervous system-independent effect in conscious rats.
47. • Gardiner SM, March JE, Kemp PA, et al.: Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats. Br J Pharmacol 2010, 161: 92-102. This study explored the role of the GLP-1 metabolite, GLP-1(9-36) in the hemodynamic effects observed with GLP-1. It also showed that GLP-1-mediated hemodynamic effects are mediated in part by the autonomic nervous system and affected by DPP-4 inhibition.
48. Ye Y, Keyes KT, Zhang C, et al. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 2010, 298: H1454-H1465.
49. Basu A, Charkoudian N, Schrage W, et al.: Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not glimepiride. Am J Physiol Endocrinol. Metab 2007, 293: E1289-E1295.
50. Nikolaidis LA, Elahi D, Shen YT et al.: Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005, 289(6): H2401-2408.
51. Ban K, Kim KH, Cho CK, et al.: Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010, 151: 1520-1531.
52. Gonzalez-Munoz C, Nieto-Ceron S, Cabezas-Herrera J, et al.: Glucagon increases contractility in ventricle but not in atrium of the rat heart. Eur J Pharmacol 2008, 587: 243-247.
53. • Tomas E and Habener JF: Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol Metab 2010, 21: 59-67. This study suggests an alternate, receptor-independent signalling mechanism for GLP-1(9-39), whereby the peptide acts intracellularly at the mitochondria to exert actions that include inhibition of reactive oxygen species and apoptosis.